Where it trades today
trading 57% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- DVA trades at 15.6x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 30.5%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- DVA is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for DVA come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for DVA. Last refresh: Sep 18, 2026, 10:57 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What DaVita Inc. does
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements;…
What analysts expect
DVA carries a buy consensus from 7 analysts, with an average price target of $219.86 versus $183.86 today (+19.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DVA generated $14.01B in trailing revenue (5.2% year over year), with a 6.0% net margin, and $1.04B of free cash flow, against $12.72B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $13.64B | $4.40B | $2.01B | $746.80M | $10.06 | $1.31B |
| 2024 | $12.82B | $4.22B | $1.95B | $936.34M | $11.02 | $1.47B |
| 2023 | $12.14B | $3.82B | $1.60B | $691.53M | $7.62 | $1.49B |
| 2022 | $11.61B | $3.40B | $1.31B | $560.40M | $6.03 | $961.14M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
DVA beside the healthcare names it is usually measured against.
What the chart is saying
DaVita Inc. trades at $183.86, 25.7% below its 52-week high. With a beta of 0.83, it shows about average sensitivity to what the wider market does.
Questions people ask about it
Is DVA a good buy right now?
DaVita Inc. trades at 15.6x earnings. This is near market average. Current risk level is High based on 30.5% volatility.
Does DVA pay dividends?
DaVita Inc. does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is DVA?
With 30-day annualized volatility of 30.5% and beta of 0.83, DVA is classified as High risk. The stock tends to be more stable than the market average.
What is the analyst price target for DVA?
The average analyst price target for DaVita Inc. (DVA) is $219.86 based on 7 analyst estimates, about 19.6% above the current price of $183.86. The published range runs from $165.00 to $270.00.
How much revenue does DVA generate?
DaVita Inc. reported $14.01B in trailing twelve-month revenue. Revenue growth is running at 5.2% year over year. Net margin sits at 6.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.